News about Global Pharma

Aurobindo Pharma USA Receives FTC Approval to Acquire Lannett Company

Aurobindo Pharma USA receives FTC approval to acquire Lannett Company in a USD 250 million deal. The transaction is expected to close before the end of June 2026.

Global Pharma | 22/06/2026 | By News Bureau

Biogen to Acquire RayThera in Deal Worth Up to USD 1 Billion to Strengthen Immunology Pipeline

Biogen has agreed to acquire immunology-focused biotech firm RayThera in a deal worth up to USD 1 billion, gaining a portfolio of anti-inflammatory drug candidates and strengthening its pipeline for immune-mediated diseases.

Global Pharma | 20/06/2026 | By News Bureau

Chiesi Presents New Metreleptin Data and Patient Care Insights at ENDO 2026

Chiesi Global Rare Diseases presented five new studies at ENDO 2026, highlighting advances in metreleptin therapy for lipodystrophy, potential combination treatments, and the urgent need to address mental health challenges and care gaps among patients with the rare disorder.

Global Pharma | 20/06/2026 | By News Bureau

Ono Pharma Seeks Expanded OPDIVO Use for Anaplastic Thyroid Cancer in Japan

Ono Pharma seeks expanded approval for OPDIVO in Japan for unresectable anaplastic thyroid cancer after a trial with Lenvima met its primary endpoint.

Global Pharma | 12/06/2026 | By News Bureau

EMA Confirms Asundexian MAA for Assessment in Secondary Prevention of Ischemic Stroke

The EMA has accepted the Marketing Authorisation Application (MAA) for asundexian, the first Factor XIa (FXIa) inhibitor under review in Europe for secondary prevention of ischemic stroke. The submission is supported by positive phase 3 OCEANIC-STROKE data.

Global Pharma | 11/06/2026 | By News Bureau |  134

NIH Identifies Cells that Protect against Inflammatory Bowel Disease

The National Institutes of Health (NIH) researchers have identified regulatory cells that help protect against Inflammatory Bowel Disease (IBD), a discovery that could lead to improved diagnosis, treatment, and disease management strategies.

Global Pharma | 10/06/2026 | By News Bureau |  108

WuXi Biologics Completes Topping-Out of Singapore Drug Product Facility

WuXi Biologics has completed the modular topping-out of its Singapore CRDMO hub drug product facility, a key manufacturing site designed to meet stringent standards. Once operational, the facility is expected to produce approximately 100 million pre-filled syringes and vials annually.

Global Pharma | 06/06/2026 | By News Bureau |  100

J&J Introduces VARIPULSE Platform for Atrial Fibrillation Treatment in India

Johnson & Johnson has launched the VARIPULSE platform in India, introducing Pulsed Field Ablation (PFA) technology for catheter ablation procedures in patients with atrial fibrillation (AFib).

Global Pharma | 04/06/2026 | By News Bureau

Aptar Pharma Files Patents, Reports Positive Preclinical Data for GLP-1 Nasal and Pulmonary Delivery

Aptar Pharma announced new patent applications and positive preclinical data supporting intranasal and pulmonary GLP-1 delivery, expanding its capabilities in inhaled and intranasal biologic drug delivery.

Global Pharma | 29/05/2026 | By News Bureau |  112

Eli Lilly and Company Reports Strong LDL-C Reduction with One-Time PCSK9 Gene Editing Therapy VERVE-102

Eli Lilly and Company reports that a single dose of investigational gene-editing therapy VERVE-102 delivered sustained reductions in PCSK9 and LDL cholesterol for up to 18 months in high-risk cardiovascular patients.

Global Pharma | 26/05/2026 | By News Bureau |  311